AMYLOIDOSIS OF THE HEART (LITERATURE REVIEW)
Abstract
Amyloidosis is a large group of diseases characterized by the accumulation of insoluble, improperly folded proteins in tissues that can be deposited systemically or in individual organs. Cardiovascular manifestations in light chain amyloidosis (LA) in almost 90% of cases lead to heart damage and, as a result, heart failure. Extra-cardiac manifestations of easily chain amyloidosis
are usually nephrotic syndrome, hepatomegaly or splenomegaly, weight loss and fatigue. There is no specific laboratory diagnosis, but high levels of B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) may indicate the possibility of this pathology and help prognosticate the condition of patients diagnosed with LA. The echocardiographic picture of patients with cardiac amyloidosis varies depending on the type of amyloidosis. This publication provides a brief overview of the clinical picture, diagnosis and specific treatment of cardiac amyloidosis.
References
Ахунова С.Ю., Барсуковская Т.А., Рафиков А.Ю., Сайфуллина Г.Б. Роль эхокардиографии в диагностике амилоидоза сердца. ПМ. 2018;1.
Мрыхин Н., Лысенко Л., Чеботарева Н., Рамеев В., Андросова Т., Рощупкина С., Гитель Е., Когарко И., Марьина С. Частота выявления и варианты моноклональной гаммапатии у больных многопрофильного терапевтического стационара. Врач. 2019;30(2):54–59. DOI: 10.29296/25877305-2019-02-11.
Adrogue H.E. Amyloidosis of the Heart and Kidney. Methodist Debakey Cardiovasc J. 2022;18(4):27–33. DOI: 10.14797/mdcvj.1150.
Alsomali D. et al. Treatment of amyloid light chain cardiac amyloidosis: systematic review and future directions. Clin Adv Hematol Oncol. 2022;20(10):609–618.
Berk J.L. et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658–2667.
Castano A. et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA cardiology. 2016;1(8):880–889.
de Carvalho, Filipe Penna, Fernanda Erthal, and Clerio F. Azevedo. The role of cardiac MR imaging in the assessment of patients with cardiac amyloidosis. Magnetic Resonance Imaging Clinics. 2019:27(3):453–463.
Dubrey S.W., Hawkins P.N., Falk R.H. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart. 2011:97(1):75–84.
Falk R.H., Alexander K.M., Liao R., Dorbala Sр. AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol. 2016;68(12):1323–41. DOI: 10.1016/j.jacc.2016.06.053.
Falk R.H. Diagnosis and management of the cardiac amyloidosis. Circulation. 2005;112(13):2047–2060.
Gertz Morie et al. Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC family practice. 2020;2:11–12.
Hassan Walid et al. Amyloid heart disease: new frontiers and insights in pathophysiology, diagnosis, and management. Texas Heart Institute Journal. 2005;32(2):178.
Kristen Arnt V. Amyloid cardiomyopathy. Herz. 2020;45(3):267–271.
Kristen Arnt V. et al. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegenerative disease management. 2019;9(1):5–23.
Kittleson Michelle M. et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142(1):e7–e22.
Kraus M.J. et al. Outcomes in patients with cardiac amyloidosis undergoing heart transplantation: the eurotransplant experience. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation. 2023;42(6):778–785. DOI: 10.1016/j.healun.2023.01.001.
Lachmann H.J., Hawkins P.N. Systemic amyloidosis. Current opinion in pharmacology. 2006;6(2):214–220.
Liang S., Liu Z., Li Q., He W., Huang H. Advance of echocardiography in cardiac amyloidosis. Heart Fail Rev. 2023;28(6):1345–1356. DOI: 10.1007/s10741-023-10332-3.
Maurer M.S. et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12(9):e006075.
Maurer M.S. et al. Design and rationale of the phase 3 ATTR-ACT clinical trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Circulation: Heart Failure. 2017;10(6):e003815.
Martinez-Naharro A. et al. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2017;70(4):466–477. DOI: 10.1016/j.jacc.2017.05.053.
Martinez-Naharro A., Philip N. Hawkins, and Marianna Fontana. Cardiac amyloidosis. Clinical Medicine. 2018;18(Suppl 2):30.
Maleszewski J.J. Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovascular pathology. 2015;24(6): 343–350.
Merlini G., Bellotti V. Molecular mechanisms of amyloidosis. New England Journal of Medicine. 2003;
(6):583–596.
Ng Perryn Lin Fei et al. Utility and pitfalls of the electrocardiogram in the evaluation of cardiac amyloidosis. Annals of noninvasive electrocardiology: the official journal of the International Society for Holter and Noninvasive Electrocardiology. 2022;27(4):e12967. DOI: 10.1111/anec.12967.
Sanchorawala V. et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood, The Journal of the American Society of Hematology. 2017;130(5):597–605.
Yamamoto H., Tomoki Y. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC heart failure. 2019;6(6):1128–1139.
